Arixtra

Arixtra is a brand name of fondaparinux, approved by the FDA in the following formulation(s):

ARIXTRA (fondaparinux sodium - injectable; subcutaneous)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: December 7, 2001
  
  Strength(s): 2.5MG/0.5ML ^[RLD][AP]


• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: May 28, 2004
  
  Strength(s): 10MG/0.8ML ^[RLD][AP], 5MG/0.4ML ^[RLD][AP], 7.5MG/0.6ML ^[RLD][AP]

Has a generic version of Arixtra been approved?

Yes. The following products are equivalent to Arixtra:

fondaparinux sodium injectable; subcutaneous

• 
  Manufacturer: DR REDDYS LABS LTD
  
  Approval date: July 11, 2011
  
  Strength(s): 10MG/0.8ML ^[AP], 2.5MG/0.5ML ^[AP], 5MG/0.4ML ^[AP], 7.5MG/0.6ML ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Arixtra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Arixtra.

See also...

• Arixtra Consumer Information (Wolters Kluwer)
• Arixtra Consumer Information (Cerner Multum)
• Arixtra Advanced Consumer Information (Micromedex)
• Arixtra AHFS DI Monographs (ASHP)
• Fondaparinux Consumer Information (Wolters Kluwer)
• Fondaparinux Consumer Information (Cerner Multum)
• Fondaparinux Subcutaneous Advanced Consumer Information (Micromedex)
• Fondaparinux Sodium AHFS DI Monographs (ASHP)